Meta-analysis of 7 randomised contrasts (2,627 participants) in non-metastatic TNBC: adding carboplatin to comparable chemotherapy improved disease control (HR 0.779) and pCR (OR 2.04), but overall survival benefit was not established (HR 0.810, p=0.107).
Meta-analysisn = 2,627
Wu et al. Survival benefit of adding carboplatin to standard anthracycline-taxane chemotherapy in triple-negative breast cancer: an updated systematic review and meta-analysis